ProMIS Neurosciences Completes Enrollment of 144 Patients in Clinical Trial
ProMIS Neurosciences announced completion of enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial, evaluating PMN310, the Company's lead therapeutic antibody candidate for the treatment of AD. The Company remains on track to conduct a blinded 6-month interim analysis in Q2 2026, including an evaluation of key plasma and cerebrospinal fluid biomarkers, followed by final unblinded 12-month top-line analysis expected in Q4 2026.
Trade with 70% Backtested Accuracy
Analyst Views on PMN
About PMN
About the author
Phoenix Mecano Valued at CHF 769, Currently 44% Undervalued
- Intrinsic Value Assessment: Utilizing a two-stage discounted cash flow model, Phoenix Mecano's intrinsic value is estimated at CHF 769, indicating a 44% undervaluation compared to its current share price of CHF 434, reflecting conservative market expectations for future cash flows.
- Future Cash Flow Forecast: The projected free cash flow is expected to grow annually, starting at €28.3 million in 2026 and reaching €57 million by 2035, indicating strong growth potential in the company's profitability and cash generation capabilities.
- Terminal Value Calculation: The estimated terminal value is €887 million, with a present value of €452 million, demonstrating the company's stable growth potential in the long term despite market volatility and industry cyclicality risks.
- Investment Risk Warning: While the company shows strong dividend performance, it has experienced a decline in earnings over the past year, and revenue growth is expected to be below 20%, necessitating investor attention to these potential risks when assessing investment value.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
ProMIS Neurosciences CEO to Participate in Evercore Healthcare Conference on December 2, 2025
- Conference Participation: ProMIS Neurosciences CEO Neil Warma will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025, showcasing the company's advancements in Alzheimer's disease treatment, which is expected to attract investor interest.
- Product Candidate: PMN310, ProMIS's lead product candidate, is designed to selectively target toxic oligomers associated with Alzheimer's disease, potentially reducing the risk of amyloid-related imaging abnormalities and improving treatment safety and efficacy.
- Clinical Trial Launch: Following encouraging results from initial trials, ProMIS has initiated the PRECISE-AD clinical trial to evaluate the safety and tolerability of multiple doses of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease, which is expected to provide critical data for clinical application.
- Technology Platform: ProMIS's EpiSelect™ platform identifies toxic misfolded proteins associated with neurodegenerative diseases, facilitating the development of antibodies and vaccines targeting these specific epitopes, demonstrating the company's innovative capabilities and market potential in the biotechnology sector.
Dow Rises by 300 Points; Waldencast Stock Takes a Dive
U.S. Stock Market Performance: U.S. stocks rose significantly, with the Nasdaq Composite gaining over 500 points, while the Dow and S&P 500 also saw increases of 0.65% and 1.40%, respectively.
Sector Movements: Communication services stocks surged by 3.1%, whereas consumer staples experienced a decline of 1.1%.
Company Highlights: Enlivex Therapeutics shares soared 48% following a major funding announcement, while Oscar Health's stock rose 21% due to potential Obamacare subsidy extensions. Conversely, Waldencast plc and Twin Hospitality Group saw significant declines in their stock prices.
Global Market Trends: European shares increased, with the eurozone's STOXX 600 up 0.44%, while Asian markets had mixed results, with Hong Kong's Hang Seng gaining and India's BSE Sensex declining.
Nasdaq Rises by 350 Points; Enlivex Therapeutics Stock Jumps Significantly
U.S. Stock Market Performance: U.S. stocks opened higher, with the Nasdaq Composite gaining over 350 points, while the Dow and S&P 500 also saw increases of 0.16% and 0.83%, respectively.
Sector Movements: Communication services stocks rose by 2.7%, while energy stocks experienced a decline of 0.9%.
Company Earnings Highlights: CureVac N.V. reported better-than-expected third-quarter earnings of $1.41 per share and sales of $63.295 million, surpassing analyst estimates.
Market Reactions: Enlivex Therapeutics shares surged 79% following a significant private placement announcement, while Clearside Biomedical shares plummeted 67% after filing for bankruptcy.
Phoenix Mecano Valued at CHF 769, Currently 44% Undervalued
- Intrinsic Value Assessment: Utilizing a two-stage discounted cash flow model, Phoenix Mecano's intrinsic value is estimated at CHF 769, indicating a 44% undervaluation compared to its current share price of CHF 434, reflecting conservative market expectations for future cash flows.
- Future Cash Flow Forecast: The projected free cash flow is expected to grow annually, starting at €28.3 million in 2026 and reaching €57 million by 2035, indicating strong growth potential in the company's profitability and cash generation capabilities.
- Terminal Value Calculation: The estimated terminal value is €887 million, with a present value of €452 million, demonstrating the company's stable growth potential in the long term despite market volatility and industry cyclicality risks.
- Investment Risk Warning: While the company shows strong dividend performance, it has experienced a decline in earnings over the past year, and revenue growth is expected to be below 20%, necessitating investor attention to these potential risks when assessing investment value.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
ProMIS Neurosciences CEO to Participate in Evercore Healthcare Conference on December 2, 2025
- Conference Participation: ProMIS Neurosciences CEO Neil Warma will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025, showcasing the company's advancements in Alzheimer's disease treatment, which is expected to attract investor interest.
- Product Candidate: PMN310, ProMIS's lead product candidate, is designed to selectively target toxic oligomers associated with Alzheimer's disease, potentially reducing the risk of amyloid-related imaging abnormalities and improving treatment safety and efficacy.
- Clinical Trial Launch: Following encouraging results from initial trials, ProMIS has initiated the PRECISE-AD clinical trial to evaluate the safety and tolerability of multiple doses of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease, which is expected to provide critical data for clinical application.
- Technology Platform: ProMIS's EpiSelect™ platform identifies toxic misfolded proteins associated with neurodegenerative diseases, facilitating the development of antibodies and vaccines targeting these specific epitopes, demonstrating the company's innovative capabilities and market potential in the biotechnology sector.
Dow Rises by 300 Points; Waldencast Stock Takes a Dive
U.S. Stock Market Performance: U.S. stocks rose significantly, with the Nasdaq Composite gaining over 500 points, while the Dow and S&P 500 also saw increases of 0.65% and 1.40%, respectively.
Sector Movements: Communication services stocks surged by 3.1%, whereas consumer staples experienced a decline of 1.1%.
Company Highlights: Enlivex Therapeutics shares soared 48% following a major funding announcement, while Oscar Health's stock rose 21% due to potential Obamacare subsidy extensions. Conversely, Waldencast plc and Twin Hospitality Group saw significant declines in their stock prices.
Global Market Trends: European shares increased, with the eurozone's STOXX 600 up 0.44%, while Asian markets had mixed results, with Hong Kong's Hang Seng gaining and India's BSE Sensex declining.
Nasdaq Rises by 350 Points; Enlivex Therapeutics Stock Jumps Significantly
U.S. Stock Market Performance: U.S. stocks opened higher, with the Nasdaq Composite gaining over 350 points, while the Dow and S&P 500 also saw increases of 0.16% and 0.83%, respectively.
Sector Movements: Communication services stocks rose by 2.7%, while energy stocks experienced a decline of 0.9%.
Company Earnings Highlights: CureVac N.V. reported better-than-expected third-quarter earnings of $1.41 per share and sales of $63.295 million, surpassing analyst estimates.
Market Reactions: Enlivex Therapeutics shares surged 79% following a significant private placement announcement, while Clearside Biomedical shares plummeted 67% after filing for bankruptcy.
